Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I suppose that’s true. Some may not the two last posts I saw. If you didn’t see them, trust me, you didn’t miss anything.
Depends on which last two you see
after ignore filter.
And others are borderline tbd….
Can anyone say with a straight face that the last two posters are any better than your favorite board pariah?
Approval or Buyout…
Neither.
BOD fighting to Keep GOLDEN PARACHUTES as they plan to
Exit
He authored his own compensation package, BOD rubber stamped it. He knew he won't be able to get drug approved, hence lousy milestones for his option vesting. Guy is crook and very cleaver.
Everybody should vote “FOR” on Proposal #4 to prevent Missling from stealing more from Shareholders if ousted.
No Golden Pachute for that MoFo!!
all options he has were given just for starting or finishing trials regardless of approval which we have NONE.
If you follow George you are nuts based on his track record. 2 things move the stock. Approval or Buyout.Period.
Nidan I know you are long. However, there is a method called short. Anavex is a "Event" driven stock. When there is garunteed long spaces of time traders have a garunteed safer period period of time to short.
Due to Missling's (IB background) poor communication, poor planning, poor trial creation, he leaves the shareholders open to be slaughtered.
Look at ANVS as an example. Unless a buyout goes down....it's as easy as printing money.
Proposal 4, limiting golden parachute, Misleading (and BOD, which is nothing but CEO, others are rubber stamp) are against it, and their reasoning is:
Why are AVXL stock holders being put through this now? WS is corrupted, IMO.
TL;DR Wait for another 10year for snake oil to cook....
"In clinical trials, patients with two copies of the APOE4 variant have much higher rates of brain bleeding and swelling associated with the treatment.
The findings suggest they should be treated at a younger age because "we know they're very, very likely to progress to impairment quickly," she said.
Dr. Samuel Gandy, an Alzheimer's researcher at Mount Sinai in New York, said the findings stress the need to enroll APOE4 homozygotes into trials designed to prevent the disease before they develop symptoms. Sperling is conducting one such trial."
Like with A2-73?????????????????
Unsure how reaffirming, for those not quite as competent as they portray themselves,
timing and the "rules of engagement" for Market action(s) is perceived as a "hedge".
However, youth and over confidence are two "virtues" that are often devoured by the true Market.
Wrong place...sorry!
Variation is the key to improving quality in an organization. Dr Deming...Variation is built into our government. Then add greed!
So Doc, thanks for the explanation below as to what may be happening with the shorts and why the stock price is stuck where it is. So if June 28 is a big day and that is when the shorts will be covering, what happens if Anavex produces some big news in the same timeframe? Lets say some of this happens: peer review that is very positive and is in a premier publication, EMA submission for AD, FDA guidance or submission as well, potential accelerated approval from both EMA and FDA, partnership ( less likely but not out of the question ), PDD trial start, etc. You get the idea. There is a ton of pent up news that is just waiting for release. Could the company be planning to release all this news like the shorts have planned for the Russell selling to cover. Could this be a major short squeeze like George has been touting? Or is that just wishful thinking? How does the layman plan for what could happen. Thanks in advance.
Of course there will be news. Anavex will issue a quarterly new release tomorrow. That is a given. Congratulations ahead of time on being right. The real question is: Will there be something potentially newsworthy announced that will be a substantive, market moving inflection point? On that score, the answer is likely not.
You promote precision medicine (not that precision medicine is relevant to Anavex) but you traffic in non-precise language in order to not be wrong. So here’s your chance to provide a more precise forecast. What constitutes real “news” in your mind? Please be precise.
Here’s my prediction: Tomorrow will be another non-event that will frustrate many shareholders who are anxiously awaiting something truly meaningful.
Expect NEWS tomorrow regarding AVXL
Management will host a conference call on Thursday, May 9, 2024, at 8:30 am ET to review financial results and provide an update on the execution of the Company’s growth strategy. Following management’s remarks, there will be a question-and-answer session.
Good luck and GOD bless,
Whilst it's true that companies sp don't always rise on approvals, there is no way that is happening with an approved AD drug.
Also often when it doesn't rise after approval it's because approval is already priced in.
Thank you Dr.Hedge!
And abandon the safety of anonymity?
Require accountability?
That is IF it were even possible to comply with your request.
Thank you for your reality check but it's hard to believe what you said re: Share price upon FDA approval.
It should be a global sensational event. lol
Are you saying it from your experience?
Your argument assumes that the shorts will buy all of the shares you mention. That is an interesting point of view.
I'm inclined not to think that will be the case. No matter what I think, the short interest report will come out on July 10th and that will include data up to and including June 28th.
So we will have some hard evidence to discuss then.
What's that got to do with the price of tea in England? Everyone knows that Russell rebalances happen a few times a year. A few months or even years from now, with some positive OLE data and a peer-review article, eventually those funds will repurchase the Anavex shares they sold if the market cap increases.
This is still a predominantly retail-owned company. Institutions had been adding to their positions, and may still be based on the ownership trend, but at some point if Blarcamesine becomes the next Lipitor the major funds will want back in and it's this transfer of shares from retail to institutions that will be the significant driver of value patient investors are hoping for.
I've never understood the notion of selling into FDA approval news for a drug like Blarcamesine. I'd rather wait a few years and let the P/E ratios determine the value of my holdings.
I would agree with the short thesis that Anavex is dead company if Donanemab was such a game changer, but it's not. It's a pain (literally) to administer, its efficacy is questionable and its safety profile is checkered. If this is the benchmark that Anavex needs to beat, I'll take that bet even if it's going to take a few more years to pay out.
We're 24-36 months away from revenue, possibly longer, unless Dr. Missling decides not to go at this alone and either partners or sells the company. The OLE data is going to be available in a few months and needs to be included in the peer-review if the goal is to maximize leverage in future negotiations. And I don't necessarily mean potential partners or buyers.
Also, keep in mind that FDA approval does not mean automatic share price increases. History is full of FDA announcements that were fundamentally positive long-term but still led to a short-term drop. The share price isn't correlated to the FDA, it's based entirely on future expected cash flow. We won't be able to model anything until a few quarters' worth of revenue comes in. That's going to be a while.
Why the EMA route? Because it's a heck of a lot easier to negotiate with single-payer government systems than the hodgepodge of for-profit American insurance companies and hospital systems.
Even so, the process takes time. A lot more than the average retail mope is willing to give the company. Waiting 10 years isn't a long time for a biotech investment to mature, and certainly not when there's a pandemic. There's also not a CEO out there who isn't going to cherry-pick when necessary and do anything possible to delay and distort bad news. It's not ideal but that's the way it works.
All signs are pointing up, except for the share price, which again is completely meaningless because there's no revenue. Based on that alone Anavex should really be trading closer to net cash value -- as should almost every non-revenue producing biotech. It's up to the FDA to decide the winners and the losers, not the stock market. I'm perfectly content watching the roulette wheel spin around and around for another couple of years while the AXONs and the BIVIs and the ANVSs et al fall by the wayside, improving our leverage even more.
Also, the new Rett trial won't take very long. A few months of testing and to anyone who thinks it will be difficult to find trial participants, go ask in the online forums if there would be interest and see how families and caregivers respond.
Blarcamesine isn't perfect. It doesn't have to be. And the bar just became lower with the FDA's new guidance, which again, is worth waiting for if it means an easier standard toward approval.
Doc: What happens if the market cap is 950 million on about June 1st?
I’m sorry that my comments offended your sense of reality.
ignatiusrielly35. Thank you for your reply. I am always learning how things work in this wonderful age of AI digital control. It's good for people to see the market they are investing in.
Broken Arrow.
Thanks ignatiusrielly35 for your market savvy.
Yep, soon, very soon and around the corner. Good! you picked up some buzzwords from clown Misleading...
Manipulators need to be taught a lesson... Talk to your senators and representatives, lets get this rolling, Where is bas2020? team up with him, he knows how to get this done, he has experience from another Miracle drug NWBO...FUDsters are suppressing the world's one and only miracle drug, which can cure anything on planet earth... Messiah Misleading deserves a Nobel Prize for bringing this drug to humanity....
It’s not possible. There is no feasible way for any private entity to trace transactions and accurately characterize them. The DTCC and the Prime Brokers like it to be opaque, despite proclaiming otherwise. Companies have tried to flush out naked shorts by, for example, issuing share dividends but the brokers just fabricate “accounting entry” shares. The only way it would ever be stopped is if they someday convert share identification to a blockchain, like crypto. Which will never happen because the large crooks basically control the market and the regulators and they make a lot of money from naked shorting.
ignatiusrielly35 - What about AVXL hiring a stock transaction auditor? Let's see who are transacting in stock activity and where the shares going? This should show who's naked shorting the stock. We can take the results to congress if the SEC doesn't act on it.
The flipside is that whatever the price is at the settlement date, the short scammers will absorb all of the forced selling they caused. Then their motivation to continue with their algo suppression will significantly abate leading into the EMA and/or FDA application. That is when we will likely see a nice rally.
There will be a tendency for other institutions to go long to try to capitalize on that. The market will get antsy, and may already be so. Hence the recent lack of non-stop downward action.
How exactly are 5 million shares “pre-covered” before they are sold/purchased? Surely you are not suggesting collusion? lol. For there are nowhere near that many options that would legally enable such covering. You are not suggesting that the short hedgies have already arranged the purchase, I hope. Again, lol.
Nope, nothing to see here. As I stated a while ago, the hedges/mm’s are intentionally forcing the Russell funds to sell shares. Welcome to the “efficient market” playground. (This is not intended for you, you know this already)
Drugs Advisory Committee (PCNS) on Monday, June 10, 2024, to discuss donanemab, which Eli Lilly and Company (NYSE: LLY) has submitted for the treatment of early symptomatic Alzheimer’s disease. The open public hearing portion of the meeting will be conducted virtually.
The Phase 3 study submitted as part of this application, TRAILBLAZER-ALZ 2, is a double-blind, placebo-controlled study to evaluate the safety and efficacy of donanemab in participants ages 60-85 years with early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia due to Alzheimer's disease) with the presence of confirmed Alzheimer's disease neuropathology. Alzheimer's disease is a progressive and fatal disease that in its early symptomatic stages affects 6-7.5 million Americans. The trial enrolled 1,736 participants, across eight countries, selected based on cognitive assessments in conjunction with amyloid plaque imaging and tau staging by positron emission tomography (PET) imaging.
The TRAILBLAZER-ALZ 2 study results were published in the Journal of the American Medical Association (JAMA). Lilly continues to study donanemab in multiple clinical trials, including TRAILBLAZER-ALZ-3, studying donanemab for the prevention of Alzheimer’s disease.
https://investor.lilly.com/news-releases/news-release-details/lilly-statement-fda-advisory-committee-meeting-donanemab-early
Expect a SHORT SQUEEZE for AVXL soon!!!
Good luck and GOD bless,
Many of the 22 M short shares are already covered. AVXL was about 3.75 on April 30 - rank day for the Russell reconstitution (compared to about 8.00 last year). We know for a fact that AVXL's proportion of the Russell 2000 and derivations thereof will be about 55% less on July 1 than the representation in the current index. About 8-10 million shares are held in Russell related funds --- hence +/- 5 million of the 22 million short coverage has been 'pre-purchased' with actual coverage occurring end of June. This is a done deal. If the market cap is under 300 million on May 31 (and MC is about that now), then the XBI will shed all 5 million shares on June 28. So 1/4 of the short position is already covered and another 1/4 could be covered in a couple weeks unless price goes up. The actual cancellation of the short position with the purchase of shed shares from the indices will occur on June 28.
Another thing for certain is that several posters will be absolutely amazed by the volume of shares traded AH on June 28.
George. Tell us something we don’t know. This is a daily occurrence. These algorithms and short bastards will never give up until the company is destroyed. The only hope is an approval somewhere which appears to be fleeting with der missing. Just what we need. Another presentation. Another downwave of the stock.
I expect a BIG nothing burger.
Look at the price/volume graph today. It is clear the the bashers, FUDsters and shorters painted the tape at the close of trading for AVXL at 4:00 PM EDT.
Good luck and GOD bless,
Only plausible one is Missling retiring soon, like really soon please.
ALZ EMA application they are not ready nor have staff for those Millions of pages.
for Rett, FDA already said we need a new trial. Check back in 2028 for results if trial is ever started.
This “growth strategy” term seems pretty general. But it could give the sp a significant boost if the “strategy” is to apply for EMA approval “next week”, FDA approval for Rett “next week” and Missling’s retirement “next week.” He seems to be all about the money so a sp boost would fall in line with him cashing out. Maybe not $5 to $100 but could be a significant rise. But, then again, maybe not.
I don’t think that partnerships are based on approval but I do think that the FDA needs to be assured that all the boxes are checked off. That is probably one of the reasons why most small biotechs have partnerships early on. I guess avxl has decided that you get better value when partnering after results but before approval or at least I hope it is that way. I would hate to think that we will have to wait another 10 months for the stock to move.
Chris, as to disclosure, if partnerships are based on approval, do they need to be revealed before approval decision is received?
I don’t like to rewrite history. Plus, I can’t edit a post on the mobile app.
Followers
|
1067
|
Posters
|
|
Posts (Today)
|
28
|
Posts (Total)
|
458548
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |